Table 1.

Association Between EQ‐5D Index Score and Outcomes

Clinical Outcome	Unadjusted		Adjusted
	HR (95% CI)	P Value*	HR (95% CI)	P Value*
MACE†	0.92 (0.90–0.94)	<0.0001	0.96 (0.93–0.98)	0.0022
MALE‡	0.90 (0.86–0.94)	<0.0001	0.93 (0.88–0.98)	0.0112
ALI requiring hospitalization§	0.97 (0.91–1.04)	0.3766	0.96 (0.90–1.03)	0.2827
Major amputation‖	0.84 (0.79–0.89)	<0.0001	0.91 (0.85–0.98)	0.0094
LER¶	0.96 (0.94–0.98)	0.0005	0.95 (0.93–0.97)	<0.0001

ABI indicates ankle–brachial index; ALI, acute limb ischemia; HR, hazard ratio; EQ‐5D, EuroQol 5‐Dimensions; LER, lower‐extremity revascularization; MACE, major adverse cardiovascular events; and MALE, major adverse limb events.

^*We used a Cox proportional hazards model, landmarked at 12 months and controlled for the baseline scores in all unadjusted and adjusted models.

^†Adjusted for Rutherford score, sex, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes mellitus, angiotensin II receptor blocker (ARB) use, prior minor amputation, prior major amputation, statin use and ABI, ticagrelor (study arm).

^‡Adjusted for Rutherford score, inclusion criteria, region, prior carotid revascularization, diabetes mellitus, prior aspirin use, prior clopidogrel use, tobacco use, ABI, estimated glomerular filtration rate (eGFR), ticagrelor (study arm).

^§Adjusted for inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use, ticagrelor (study arm).

^‖Adjusted for Rutherford score, inclusion criteria, prior coronary artery bypass graft (CABG), diabetes mellitus, statin use, prior major amputation, prior minor amputation, ABI, weight, ticagrelor (study arm).

^¶Adjusted for inclusion criteria, region, ABI, tobacco use, diabetes mellitus, prior clopidogrel use, prior aspirin use, ticagrelor (study arm).